RNA Clinical Trials Articles

31. Metaphorical mRNA: An Argument For (More) Creativity In RNA Therapeutics 1/25/2023

    In putting together my mRNA outlook presentation for November's 2022 AGC CDMO Summit, I realized there is one opportunity that should be top of mind for the RNA therapeutics industry in the years to come. We all, regardless of our functional area in the industry (i.e., manufacturing, quality, R&D, commercial), need to figure out how we can make this important science more accessible to populations around the world. 

32. Defining The RNA Therapeutics Industry In 2023 1/16/2023

    Four executives outline which industry challenges, strategic considerations, and opportunities should be top of mind as RNA therapeutics companies establish their to-do lists for 2023.

33. mRNA & RNA Therapeutics In 2023: Where Do We Go From Here? 12/7/2022

    To figure out what the future holds for companies in the RNA sector of the ATMP space, I sat down with four executives to discuss their wildest hopes, dreams, and expectations. As you’ll note, there is no shortage of work facing the RNA therapeutics industry in the year(s) ahead. But there’s also a lot for which we can hope.

34. DTx Pharma And The Near-Term Future Of RNA Therapeutics 11/21/2022

    To learn more about the near-term future of RNA therapeutics, the advantages of short interfering RNA (siRNA) over other RNA therapeutics and more, I caught up with DTx Pharma's CEO Arthur Suckow.

35. The Promising Future Of Oligonucleotides 10/31/2022

    Episode 35 of Cell & Gene: The Podcast features Dr. Michelle Mellion, PepGen’s SVP Head of Clinical Development at Cambridge, MA-based biotech PepGen. In it, Dr. Mellion talks all about the company’s oligonucleotide therapeutics that were developed to treat severe neuromuscular and neurologic diseases, such as Duchenne Muscular Dystrophy (DMD).

36. A (More) Mature mRNA Therapeutics Industry: 4 Best Practices To Get There 9/27/2022

    Throughout the two-day mRNA Therapeutics Summit, there were four key takeaways that clearly demonstrated how the mRNA industry could incrementally achieve one speaker's industry prediction that, within the next 10 years, every person in the world will have had the opportunity to benefit from mRNA.

37. Breakdown Of Cell & Gene Live: Advancements In Targeted mRNA Delivery 9/21/2022

    During our Cell & Gene Live, Advancements in Targeted mRNA Delivery, Dr. Murat Kalayoglu, CEO of Cartesian Therapeutics, Walter Strapps, Ph.D., Co-Founder and CEO of Carver Biosciences, and I spent the hour talking about the delivery of mRNA-based therapeutics. Our expert panelists discussed the specific challenges and opportunities in delivering conventional RNA therapeutics clinically, as well as the specific challenges and opportunities in delivering the RNA cell therapies clinically. You can view the full-length presentation here. For your convenience, we’ve broken down the hour into bite-size chunks based on the important topics we discussed throughout the hour.

38. Capstan Therapeutics' Next Steps For In Vivo CAR Therapies 9/19/2022

    Capstan Therapeutics is a brand-new biotech company dedicated to developing and delivering precise in vivo cell engineering to patients. With $165 million in financing, Capstan Therapeutics aims to build on the foundational insights of leaders in mRNA and cell therapy from the University of Pennsylvania. Laura Shawver, Ph.D., leads the company as President and CEO, and on the heels of the biotech’s recent news, I caught up with her to learn more about the company’s plans for developing in vivo CAR therapies.

39. Don't Get Uppity: Match mRNA Science To Your Capabilities — And Vice Versa 9/6/2022

    This article is part one of a four-part series unpacking four of my biggest takeaways from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

40. The Promise Of Gene Silencing To Treat Not-So-Rare Diseases 9/2/2022

    In this last article in the series on siRNA, I examine its potential for treating not-so-rare and common diseases. Unlike rare diseases, which are often caused by pathological genetic mutations, common diseases may be associated with genetic variants that are not pathological. I look at cardiovascular disease and iron flux redux in particular.